p53 Expression in neurofibroma and malignant peripheral nerve sheath tumor: An immunohistochemical study of sporadic and NF1-associated tumors

American Journal of Clinical Pathology

Volumn 106, Issue 3, 1996, Pages 282-288

  Halling, Kevin C ^a   Scheithauer, Bernd W ^a   Halling, Amy C ^a   Nascimento, Antonio G ^a   Ziesmer, Steven C ^a   Roche, Patrick C ^a   Wollan, Peter C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Malignant peripheral nerve sheath tumor; Neurofibroma; p53; Prognosis; Tumor suppressor gene

Indexed keywords

MONOCLONAL ANTIBODY; NEUROFILAMENT PROTEIN; PROTEIN P53; PROTEIN S 100; VIMENTIN;

ADULT; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NERVE SHEATH TUMOR; NEUROFIBROMA; NEUROFIBROMATOSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 0029781715     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/106.3.282     Document Type: Article

References (46)

1. Riccardi VM, Eichner JE. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. Baltimore: Johns Hopkins University Press. 1986, pp 214-266.
2. Barker D, Wright E, Nguyen K, et al. Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science 1987;236:1100-1102.
3. Seizinger BR, Rouleau GA, Ozelius LJ, et al. Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell 1987;49:589-594.
4. Viskochil D, White R, Cawthon R. The neurofibromatosis type 1 gene. Annu Rev Neurosci 1993;16:183-205.
5. Brasfield RD, Das Gupta TK. von Recklinghausen's disease: A clinicopathological study. Ann Surg 1972;175:86-104.
6. Riccardi VM, Powell PP. Neurofibrosarcoma as a complication of von Recklinghausen neurofibromatosis. Neurofibromatosis 1989;2:152-165.
7. Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors: A clinicopathologic study of 120 cases. Cancer 1986;57:2006-2021.
8. Andreassen Å, Øyjord T, Hovig E, et al. p53 abnormalities in different subtypes of human sarcomas. Cancer Res 1993;53: 468-471.
9. Leach FS, Tokino T, Meltzer P, et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993;53:2231-2234.
10. Oliner JD. Discerning the function of p53 by examining its molecular interactions. Bioessays 1993;15:703-707.
11. Toguchida J, Yamaguchi T, Ritchie B, et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 1992;52:6194-6199.
12. Menon AG, Anderson KM, Riccardi VM, et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci USA 1990;87:5435-5439.
13. Kawai A, Noguchi M, Beppu Y, et al. Nuclear immunoreaction of p53 protein in soft tissue sarcomas: A possible prognostic factor. Cancer 1994;73:2499-2505.
14. Kindblom L-G, Ahlden M, Meis-Kindblom J, Stenman G. Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki 67 in benign and malignant peripheral nerve sheath tumours. Virchows Arch 1995;427:19-26.
15. Porter PL, Gown AM, Kramp SG, Coltrera MD. Widespread p53 overexpression in human malignant tumors. Am J Pathol 1992;140:145-153.
16. Kerns BJ, Jordan PA, Moore MH, et al. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem 1992;40:1047-1051.
17. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-526.
18. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-1327.
19. Selter H, Montenarh M. The emerging picture of p53. Int J Biochem 1994;26:145-154.
20. Harris CC. p53: At the crossroads of molecular carcinogenesis and risk assessment. Science 1993;262:1980-1981.
21. Levine AJ, Perry ME, Chang A, et al. The 1993 Walter Hubert Lecture: The role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994;69:409-416.
22. Lane DP. p53, guardian of the genome. Nature 1992;358:15-16.
23. Marx J. How p53 suppresses cell growth. Science 1993;262:1644-1645.
24. Chang F, Syrjanen S, Kurvinen K, Syrjanen K. The p53 tumorsuppressor gene as a common cellular target in human carcinogenesis. Am J Gastroenterol 1993;88:174-186.
25. Malkin D. p53 and the LiFraumeni syndrome. Cancer Genet Cytogenet 1993;66:83-92.
26. Soussi T, Leblanc T, Baruchel A, Schaison G. Germline mutations of the p53 tumor-suppressor gene in cancer-prone families: A review. Now Rev Fr Hematol 1993;35:33-36.
27. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-221.
28. Lavigeur A, Maltby V, Mock D, et al. High incidence of lung, bone and lymphoid tumours in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 1989;1:7721-7730.
29. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1992;248:76-79.
30. Gerbes AL, Caselmann WH. Point mutations of the p53 gene, human hepatocellular carcinoma and aflatoxins. J Hepatol 1993;19:312-315.
31. Berchuck A, Kohler MF, Marks JR, et al. The p53 tumor-suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994;170:246-252.
32. Field JK, Pavelic ZP, Spandidos DA, et al. The role of the p53 tumor-suppressor gene in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1993;119:1118-1122.
33. Louis DN. The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 1994;53:11-21.
34. Thapar K, Scheithauer BW, Kovacs K, et al. p53 expression in pituitary adenoma and carcinoma: Correlation with invasiveness and tumor growth fraction. Neurosurgery 1996;38:765-770.
35. McNutt NS, Saenz-Santamaria C, Volkenandt M. Abnormalities of p53 protein expression in cutaneous disorders. Arch Dermatol 1994;130:225-232.
36. Ichikawa A, Hotta T, Saito H. Mutations of the p53 gene in B-cell lymphoma. Leuk Lymphoma 1993;11:21-25.
37. Malkin D, Jolly KW, Barbier N, et al. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 1992;326:1309-1315.
38. Soini Y, Vahakangas K, Nuorva K, et al. p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumors. J Pathol 1992;168:29-33.
39. Nigro JM, Baker SJ, Preissinger AD, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989;342: 705-708.
40. Momand J, Zambetti GP, Olson DC, et al. The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;691:1237-1245.
41. Skuse GR, Kosciolek BA, Rowley PT. Molecular genetic analysis of tumors in von Recklinghausen neurofibromatosis: Loss of heterozygosity for chromosome 17. Genes Chromosom Cancer 1989;1:36-41.
42. Bishop JM. Molecular themes in oncogenesis. Cell 1991;64:235-248.
43. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;343:377-381.
44. Nakai H, Misawa S, Toguchida J, et al. Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. Cancer Res 1992;52:6588-6593.
45. Andersen TI, Holm R, Nesland JM, et al. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 1993;68: 540-548.
46. Hamelin R, Laurent-Puig P, Olschwang S, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-48.